跳转至内容
Merck
CN

C9854

Monoclonal Anti-CD86 antibody produced in mouse

~0.5 mg/mL, clone B72-H2, purified immunoglobulin, buffered aqueous solution

别名:

Anti-B7-2

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

UNSPSC Code:
12352203
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

biological source

mouse

conjugate

unconjugated

antibody form

purified immunoglobulin

clone

B72-H2, monoclonal

form

buffered aqueous solution

mol wt

antigen ~75 kDa

species reactivity

human

concentration

~0.5 mg/mL

technique(s)

flow cytometry: suitable, immunohistochemistry (frozen sections): suitable

isotype

IgG2a

shipped in

wet ice

Gene Information

human ... CD86(942)

General description

CD86 is one of two ligands (the other is CD80) for CD152 (CTLA-4) and CD28. CD86 acts as co-stimulatory molecule in eliciting T cell help during antigen presentation. Antigen presentation in the absence of sufficient co-stimulation involving CD86/CD80 can induce tolerance. CD86 appears to play a role distinct from CD80 in T helper cell differentiation. CD86 is rapidly induced on the surface of activated B cells, T cells or monocytes and is expressed at high levels on dendritic cells. It is also found on malignant Hodgkin and Reed-Sternberg (H-RS) cells in Hodgkin′s disease.

Immunogen

recombinant extracellular domain of human CD86.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 0.08% sodium azide.

Preparation Note

Prepared from tissue culture supernatant, purified using protein G.

法规信息

新产品

此项目有


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Laura J Vella et al.
Cancer immunology research, 2(4), 351-360 (2014-04-26)
Combination therapy with BRAF and MEK inhibition is currently in clinical development for the treatment of BRAF-mutated malignant melanoma. BRAF inhibitors are associated with enhanced antigen-specific T-lymphocyte recognition in vivo. Consequently, BRAF inhibition has been proposed as proimmunogenic and there
David G Hancock et al.
PloS one, 9(6), e100613-e100613 (2014-06-21)
Dendritic cells (DCs) are critical for regulating CD4 and CD8 T cell immunity, controlling Th1, Th2, and Th17 commitment, generating inducible Tregs, and mediating tolerance. It is believed that distinct DC subsets have evolved to control these different immune outcomes.
Yuanji Ma et al.
Oxidative medicine and cellular longevity, 2014, 148798-148798 (2014-08-12)
Dendritic cells (DCs), which are highly proficient antigen-presenting cells, play a complex role in both the initiation and progression of atherosclerosis. We tested the hypothesis that the anti-inflammatory and antioxidant effects of atorvastatin may be partly mediated by the phosphatidylinositol
Kazuyuki Kasahara et al.
Journal of the American Heart Association, 3(2), e000719-e000719 (2014-04-24)
Accumulating evidence suggests that the balance between pathogenic effector T cells (Teffs) and regulatory T cells (Tregs) may be important for controlling atherosclerotic disease. We hypothesized that a combination therapy with anti-CD3 antibody (CD3-Ab) and IL-2/anti-IL-2 monoclonal antibody complex (IL-2
Yuling Zhao et al.
PloS one, 9(9), e106867-e106867 (2014-09-18)
The pathobiology of Parkinson's disease (PD) is associated with the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) projecting to the striatum. Currently, there are no treatments that can halt or reverse the course of PD; only

相关内容

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持